Watch this on-demand webinar held on April 07, 2022, to learn strategies to shorten timelines while minimizing safety and regulatory risks for biologics development. The speaker will also highlight on CLD platform options and how testing across multiple platforms simultaneously can help reduce timelines and reduce risks.
The majority of new chemical entities (NCEs) are limited by poor solubility and bioavailability issues and are unable to proceed to the clinical development phase despite promising therapeutic activity.
In this webinar you will learn about various formulation techniques like solutions, microemulsions, amorphous solid dispersions and nanosuspensions.
Dr. Sufia Karim
Director, Cell Line Development, Aragen Life Sciences
Dr. Sufia Karim
Director, Cell Line Development, Aragen Life Sciences
